Work

2022-RA-464-ESGO A phase i dose escalation and expansion cohort trial of carboplatin and gemcitabine with the ATR inhibitor berzosertib in first or second recurrence platinum sensitive epithelial ovarian, peritoneal, and fallopian tube cancer

Year: 2022

Type: article

Study design: Clinical Trial

Source: International Journal of Gynecological Cancer

DOI: 10.1136/ijgc-2022-esgo.512

Authors: Andrea E Wahner Hendrickson, Nathan Foster, Bradley R Corr, Linda Duska, Merry J Markham, Kristina Butler, Eugenia Girda, Rachel Ware Miller, Katherine Arneson, Katherine Gano, Janelle Johnson, Geoffrey Shapiro, Larry Rubinstein, S Percy Ivy, Elise Kohn, Alex Adjei, Scott Kaufmann

Institutions: Mayo Clinic, University of Colorado Cancer Center, University of Colorado Anschutz, University of Virginia, University of Florida, Mayo Clinic in Arizona, Rutgers Cancer Institute, University of Kentucky, Markey Cancer Center, Dana-Farber Cancer Institute, National Institutes of Health, National Cancer Institute

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4312697377

FWCI:

Cites:

Cited by:

Related to: 10